Every letter we have printed

The claim that a reproduced spectrum is worth more than any number in the document seems overstated. Most buyers cannot read a spectrum, and a printed image invites false confidence rather than scrutiny.

The reference population for most intervals is a convenience sample of donors or staff, and its age and sex composition is rarely printed with the interval. Where it is, it is often not the population reading the result.

Biological variation within one person is smaller than the variation between people for many analytes, which is why a series of results on one individual is far more informative than a single result against a population interval.

Estimated glomerular filtration rate is calculated from creatinine, so everything that moves creatinine moves the estimate. During substantial change in body composition the equation is being applied outside the conditions in which it was derived, and the estimate carries more uncertainty than the single number suggests.

I administer a small purchasing budget and I have stopped treating marks of this kind as evidence at all. Not because they are dishonest, but because I cannot tell from the mark which of the honest cases I am looking at, and a signal I cannot decode is not a signal.

Your series has changed how I read a storefront and I would add one habit for other readers. Before looking at any mark, find the date. If there is no date anywhere on the page, the mark is decoration and the rest of the page should be read in that light.

Custody matters most exactly when the result is bad, which is when nobody has a record. The discipline has to be in place before it is needed, and the incentive to establish it only appears afterwards.

Capillary electrophoresis is the forgotten answer here. It separates on charge-to-size in free solution, it needs a few nanolitres, and for anybody who already has the instrument it is an afternoon. The barrier is not cost or difficulty; it is that hardly anyone in this trade has been trained on it.

Ion-exchange deserves a place beside size-exclusion in your list of second principles. Deamidation shifts charge without shifting mass or hydrophobicity appreciably, so it is close to invisible in reversed phase and obvious on a charge-based separation. For an ageing peptide it is the question worth asking.

Your article argues for two orthogonal methods and reports the lower figure, but the people running a single twelve-minute method have a cost story you do not address. A full orthogonal pair doubles the turnaround and at least doubles the cost, which is why the market does not do it. The criticism of method disclosure is fair. The criticism that a single method is wrong is unfair to the constraints people operate under.

The argument I would add is a procurement one. My purchasing system has a field for purity and no field for method, so a buyer who wanted to record the gradient would have nowhere to put it. Until the forms change, the number will keep travelling alone, and no amount of editorial pressure on laboratories will alter that.

A short defence of long run times. Most of the disputes described in this series would be settled by adding fifteen minutes to the gradient and letting the late-eluting material come off inside the run rather than in the next injection. Throughput is the real reason methods are short, and throughput is a commercial value, not an analytical one.

Stopping without telling anybody is common and it makes the observational data worse than it looks, because somebody recorded as continuing may have stopped months earlier. Persistence measured from prescription records and persistence in fact are different quantities.

Reasons given in public forums are shaped by the audience. A community that values persistence will hear fewer accounts of stopping, and a community that is sceptical will hear more. Neither is a sample of anything.

The trial designs answer a question about the drug and the reader has a question about themselves. A mean regain curve tells an individual very little about their own trajectory, and the variance around those means is rarely printed with the same prominence.

Nobody reports what maintenance costs in attention. The accounts I find most credible describe a low but continuous administrative load — ordering, storing, timing, monitoring — and that load is invisible in every clinical endpoint.

Timing matters as much as reason. Stopping in week three and stopping in year three are different events with different consequences, and reporting a single discontinuation rate for a study collapses that entirely.

Reasons recorded at the point of sale would be a different dataset entirely and one nobody has ever assembled. A supplier knows precisely who stopped ordering and when, and has no reason at all to publish it.

Cost is a maintenance variable and it is treated as though it were outside the clinical question. For most people the sustainable dose is the affordable one, and a plan that ignores that will be abandoned rather than followed.

Cost is the reason least often recorded and most often given in private. Every survey I have seen collapses it into an "other" category, and it is very likely the largest single entry in the list.

Reasons cluster by phase. Early discontinuation is dominated by tolerability, late discontinuation by cost and circumstance, and reporting them as a single distribution loses the only structure in the data.

The costs compound quietly. A monthly figure that seemed acceptable at the start becomes a substantial annual commitment, and almost nobody in the accounts I read did that arithmetic before beginning.

The claim that stopping does not leave you worse off than baseline is a group-level claim about trial arms. Individuals can and do overshoot. Your phrasing invites readers to conclude otherwise.

A properly blind purchase means buying as an ordinary customer, from the ordinary catalogue, with no indication that the vial is going anywhere but a domestic address. Anything less and the supplier has had an opportunity, however small, to treat that order differently.

Sample size defeats most of what is published. A single blind purchase from one supplier tells you about one vial. It is worth having and it is not a characterisation of anything, and the gap between those two statements is where most confusion in this market lives.

I would like badges to carry a date in the image itself, not in a tooltip and not in a linked report. Anything that requires a second click will not be clicked, and a design that depends on diligence the reader does not have is a design that has chosen its outcome.

Pooled analyses across trials with different collection methods produce a number that describes no study, and they are the source of most widely quoted figures in this area. The pooling is legitimate and the resulting precision is illusory.

Self-reported incidence collected in online communities is not comparable with trial incidence in any direction, and it is put side by side with it regularly. Different populations, different definitions, different collection, one chart.

Tachyphylaxis in the emptying effect is a real observation and it is the mechanistic basis for symptoms easing at a stable dose. Stating it explicitly would help readers understand why the advice is to hold rather than to stop.

Meal composition interacts with the mechanism in ways the literature has measured and popular coverage never mentions. Fat content in particular changes emptying substantially at baseline, before anything else is introduced.

A short thank you for the reference desk, which I use more often than the articles. Somebody has clearly spent a great deal of time on material that will never be anybody’s headline.

Vitamin B12 status is imperfectly captured by a serum level, and the confirmatory markers are available and rarely ordered. Where the question genuinely matters, the serum value alone is the weakest form of the answer.

Ferritin is an acute phase reactant, so a value taken during inflammation says something about the inflammation. Pairing it with a marker that is not acute phase is the standard remedy and it is routinely omitted.

My eGFR has risen from 71 to 84 over fourteen months of treatment and I have lost twenty-six kilograms. My prescriber described this as the drug protecting my kidneys. Having read your creatinine section, I suspect it is mostly that I have less muscle. Which of us is right?

As a biomedical scientist I would add one point to your reference-interval section: many laboratories do not derive their own intervals at all. They adopt the manufacturer interval for the platform, which was established in a population that may have nothing to do with the one being tested. The interval on the report can be a document about a different country.

An interlaboratory comparison needs a homogeneous material and a stated assigned value, which is why proficiency schemes in other sectors are run by a body that prepares the material rather than by a participant. Until somebody does that here, these exercises measure agreement rather than accuracy.

The spread you reported is, by the standards of interlaboratory comparison in sectors I have worked in, unremarkable. That is not a criticism of your reporting; it is a correction to the alarm some readers will take from it. Two laboratories differing by a point on a chromatographic purity are behaving normally.

The duration after withdrawal is the parameter that determines the headline, and it varies between studies more than any other design feature. A curve measured to week twenty and a curve measured to week eighty tell very different stories about the same phenomenon.

Participants who complete a run-in and are then randomised are a selected group by construction, so the withdrawal arm is populated by people who tolerated and responded. Generalising from them to everybody who stops overstates what is known.

The population that has maintained for several years is small, self-selected and largely unstudied, and it is the population everybody is most curious about. That mismatch is the defining feature of this subject.